Cheng Y et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med 2024;391(14):1313-27. Abstract
Dowlati A et al. DeLLphi-306 trial: A phase 3 study of tarlatamab after concurrent chemoradiotherapy in limited-stage small cell lung cancer. WCLC 2024;Abstract PT01.13.02.
Dowlati A et al. Sacituzumab govitecan as second-line treatment in patients with extensive stage small cell lung cancer. WCLC 2024;Abstract OA04.04.
Einsele H et al. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer 2020;126(14):3192-201. Abstract
Horn L et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379(23):2220-9. Abstract
Johnson ML et al. Intracranial response in patients (pts) with baseline (BL) brain metastases (BM) and extensive-stage (ES) small cell lung cancer (SCLC) treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study. ESMO 2024;Abstract 1787P.
Lau S et al. Tarlatamab with a PD-L1 inhibitor as first-line maintenance after chemo-immunotherapy for ES-SLCLC: DeLLphi-303 phase 1b study. WCLC 2024;Abstract OA10.04.
Megyesfalvi Z et al. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin 2023;73(6):620-52. Abstract
Midde N et al. Exposure-response analyses to support ph3 dose selection for I-DXd (ifinatamab deruxtecan) in extensive stage SCLC patients. WCLC 2024;Abstract PT01.13.05.
Ohe Y et al. BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). ASCO 2024;Abstract 8001.
Owonikoko TK et al. IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC). ASCO 2024;Abstract TPS8126.
Paz-Ares L et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study. J Clin Oncol 2023;41(16):2893-903. Abstract
Paz-Ares L et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 2022;7(2). Abstract
Paz-Ares L et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet 2019;394(10212):1929-39. Abstract
Perol M et al. Tarlatamab plus durvalumab as first-line maintenance in extensive-stage small cell lung cancer: DeLLphi-305 phase 3 trial. WCLC 2024;Abstract PT01.13.02.
Qui M et al. DLL3-targeted CAR-T therapy of small cell lung cancer utilizing circular RNA. WCLC 2024;Abstract MA17.13.
Rudin CM et al. IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC). ESMO 2024;Abstract 1812TiP.
Rudin CM et al. Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis of Ideate-lung01. WCLC 2024;Abstract OA04.03.
Sands J et al. Tarlatamab sustained clinical benefit and safety in previously treated SCLC: DeLLphi-301 phase 2 extended follow-up. WCLC 2024;Abstract OA10.03.
Senan S et al. Patient-reported outcomes (PROs) with consolidation durvalumab versus placebo following cCRT in limited-stage SCLC: ADRIATIC. WCLC 2024;Abstract MA17.04.
Spigel DR et al. ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). ASCO 2024;Abstract LBA5.
Stieglmaier J et al. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin Biol Ther 2015;15(8):1093-9. Abstract
Wang J et al. Efficacy and safety of HS-20093 in extensive stage small cell lung cancer in a multicenter, phase 1 study (ARTEMIS-001). WCLC 2024;Abstract OA04.06.